Skip to main content

Table 2 Patients’ baseline characteristics

From: Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial

  UC-MSC (n = 21) Placebo (n = 24) p value
Age, years 64 (10.4) 63.2 (11.4) 0.82
Male sex 17 (81%) 20 (83.3%) 1
Body mass index 28.6 (3.5) 28 (5.5) 0.68
Obesity 7 (33.3%) 6 (25%) 0.54
Sepsis-related Organ-Failure Assessment score 5.5 (2.7) 5.9 (2.7) 0.64
Mean arterial pressure, mm Hg 91.3 (18.3) 81.5 (16.9) 0.07
On vasopressors 5 (23.8%) 14 (58.3%) 0.02
Comorbidities    
 Chronic obstructive pulmonary disease 0 (0%) 1/15 (6.7%) 1
 Active smoking 0 (0%) 0 (0%) 0.24
 Chronic heart failure 0 (0%) 0 (0%) 1
 Atrial fibrillation 2/15 (13.3%) 0 (0%) 0.21
 Hypertension 11/15 (73.3%) 10/15 (66.7%) 0.47
 Coronary artery disease 2/15 (13.3%) 2/15 (13.3%) 1
 Stroke 2/15 (13.3%) 1/15 (6.7%) 0.59
 Immunodeficiency 0 (0%) 0 (0%) 1
 Active neoplasia 0 (0%) 0 (0%) 1
Chronic corticosteroid intake 0 (0%) 0 (0%) 1
Immunomodulatory drugs 2/17 (11.8%) 0 (0%) 0.2
Respiratory characteristics    
 Ventilatory support (NIV and/or HFNO) 10 (47.6%) 4 (16.7%) 0.02
 Invasive mechanical ventilation 11 (52.4%) 20 (83.3%) 0.02
 Tidal volume, mL/kg PBW 6.2 (0.7, n = 11) 6.3 (0.8, n = 20) 0.72
 Plateau airway pressure, cm H2O 21.8 (4.2, n = 10) 24.8 (5.1, n = 17) 0.12
 PEEP 10.8 (2.9, n = 11) 11.2 (3.2, n = 20) 0.72
 Driving pressure 11.3 (4.3, n = 10) 13.2 (3.9, n = 17) 0.25
 Compliance, mL/cm H2O 45.2 (27.8, n = 10) 35.2 (14.9, n = 17) 0.29
 SpO2, % 94.6 (3.4) 96.0 (3.0, n = 23) 0.16
 PaO2/FiO2, mm Hg 156.2 (68.2) 171.2 (72.9) 0.53
 Lung injury score 3.0 (0.7) 2.8 (0.5) 0.61
 PaCO2, mm Hg 40 (8.5) 43.2 (9.8) 0.17
 pH 7.41 (0.1) 7.37 (0.1) 0.27
 Neuromuscular blocking agents 6 (28.6%) 16 (66.7%) 0.01
Ventilation mode    
 Volume control 11/11 (100%) 19/20 (95%) 1
 Pressure control 0 (0%) 0 (0%) 1
 Pressure support 0 (0%) 1/20 (5%) 1
  1. Values are expressed as mean (standard deviation) or number (%). Information was available for all patients, unless indicated otherwise
  2. HFNO high-flow nasal oxygen therapy, NIV non-invasive ventilation, PaCO2 partial pressure of arterial carbon dioxide, PaO2/FiO2 ratio of partial pressure of oxygen to fractional inspired oxygen, PBW predicted body weight, PEEP positive end-expiratory pressure, SpO2 peripheral capillary oxygen saturation, UC-MSCs umbilical cord-derived mesenchymal stromal cells